christopher vinnard, md, mph, msce clinical assistant
TRANSCRIPT
![Page 1: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/1.jpg)
Christopher Vinnard, MD, MPH, MSCEClinical Assistant ProfessorNew Jersey Medical SchoolRutgers, The State University of New Jersey
![Page 2: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/2.jpg)
![Page 3: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/3.jpg)
![Page 4: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/4.jpg)
![Page 5: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/5.jpg)
![Page 6: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/6.jpg)
![Page 7: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/7.jpg)
![Page 8: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/8.jpg)
1. The pathogen must be present in all cases of disease. 2. The pathogen can be
isolated from diseased host and grow in pure culture.
3. The pathogen from the pure culture must cause the disease when inoculated into a healthy, susceptible laboratory animal.
4. The pathogen must be reisolated from the new host and shown to be the same as the originally inoculated pathogen.
![Page 9: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/9.jpg)
Contagion
Disease
Infection
Exposure
![Page 10: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/10.jpg)
Exposure Infection
![Page 11: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/11.jpg)
DROPLET
Transmission within meter of source
Inoculum typically has large numbers of organisms
Access to vulnerable sites in oropharynx and upper airway
Hand washing may be effective
AIRBORNE
Transmission within shared breathing space
Inoculum may have small numbers of organisms
Access to vulnerable sites in alveoli
Hand washing not effective
![Page 12: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/12.jpg)
Airborne droplet nuclei up to 6 hours
Alveolar macrophages are first line of defense
M. tb survives inside the macrophage-prevents fusion of phagosome and lysosome
Barry, Nat Rev Microbiol, 2009
![Page 13: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/13.jpg)
INNATE
Nonspecific factors- within hours of exposure
Triggered by chemical properties of the antigen
Chemokines attract circulating monocytes, transform into macrophages
ADAPTIVE
Antigen specific immune responses
Slowly develops in TB infection
Delayed response may contribute to latency
![Page 14: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/14.jpg)
Airborne droplet nuclei up to 6 hours
Alveolar macrophages are first line of defense
M. tb survives inside the macrophage-prevents fusion of phagosome and lysosome
Containment of infection with adaptive immune response
Barry, Nat Rev Microbiol, 2009
![Page 15: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/15.jpg)
Pai, M. et al. Nat. Rev. Dis. Primers, 2016
![Page 16: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/16.jpg)
QFT ResultNil
(IU/mL)TB Ag-Nil (IU/mL)
Mitogen-Nil(IU/mL)
Positive < 8.0 > 0.35 and > 25% Nil value Any
Negative < 8.0 < 0.35 > 0.5
Indeterminate < 8.0> 0.35 and < 25% of Nil
value< 0.5
Indeterminate > 8.0 Any Any
Nil Control
ESAT-6Panel A
CFP10Panel B
Positive Control
T-SPOT®.TB Package Insert. Marlborough, MA: Oxford Immunotec; 2010
T-SPOT®.TB
QuantiFERON®-TB Gold Package Insert. Cellestis, Inc. Valencia, CA; 2011
QuantiFERON®-TB Gold
![Page 17: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/17.jpg)
![Page 18: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/18.jpg)
Fibrotic
Non-necrotizing
Caseous
![Page 19: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/19.jpg)
Airborne droplet nuclei up to 6 hours
Alveolar macrophages are first line of defense
M. tb survives inside the macrophage-prevents fusion of phagosome and lysosome
Containment of infection with adaptive immune response
Tissue granulomas: microscopic +/-macroscopic
Barry, Nat Rev Microbiol, 2009
![Page 20: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/20.jpg)
Infection Disease
![Page 21: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/21.jpg)
![Page 22: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/22.jpg)
![Page 23: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/23.jpg)
Advanced HIV
Close contact
CXR evidence of old TB (untreated)
Chronic renal disease
TNF-alpha inhibitor
Poorly controlled DM
Underweight
SmokingNEJM 2011; 364(15): 1441-8
![Page 24: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/24.jpg)
Exposure LTBI Active TB
HistoryNo testing available
TSTIGRA
AFB SmearAFB CulturePCR Based testingBiopsy and Histology
Window Prophylaxis One drug
Primarily one drug regimens(INH or Rifampin)
Two drug -12 week- regimen
Initial 4 drug RegimenTailored if DST available
1
10-100
100,000,000,000(cavitary)
Organism burden
Exposure to LTBI (test conversion) = 8-10 weeks LTBI to Active Disease timeline depends on Host Immune System – weeks to years
Slide courtesy Dr. E. Jane Carter
![Page 25: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/25.jpg)
Airborne droplet nuclei up to 6 hours
Alveolar macrophages are first line of defense
M. tb survives inside the macrophage-prevents fusion of phagosome and lysosome
Containment of infection with adaptive immune response
Tissue granulomas: microscopic +/-macroscopic
Active TB disease =Primary progressive + Reactivation from latency
Barry, Nat Rev Microbiol, 2009
![Page 26: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/26.jpg)
Latent tuberculosis
Active pulmonary tuberculosis
Active extra-pulmonary tuberculosis
HIV
+
+
HIV and Tuberculosis
![Page 27: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/27.jpg)
Paratracheal and hilar lymphadenopathy
http://www.hiv.va.gov/provider/image-library/tb.asp?post=1&slide=46
![Page 28: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/28.jpg)
Annals of Thoracic Medicine - Vol 5, Issue 4, October-December 2010
Right upper lobe consolidation
![Page 29: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/29.jpg)
https://radiopaedia.org/cases/miliary-tuberculosis-2
![Page 30: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/30.jpg)
![Page 31: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/31.jpg)
WHO Global Tuberculosis Report, 2015
![Page 32: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/32.jpg)
![Page 33: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/33.jpg)
Disease Contagion
![Page 34: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/34.jpg)
Airborne droplet nuclei up to 6 hours
Alveolar macrophages are first line of defense
M. tb survives inside the macrophage-prevents fusion of phagosome and lysosome
Containment of infection with adaptive immune response
Tissue granulomas: microscopic +/-macroscopic
Active TB disease =Primary progressive + Reactivation from latency
Barry, Nat Rev Microbiol, 2009
![Page 35: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/35.jpg)
Infectiousness of index patient (source) Cough Smear microscopy grade Cavitary disease
Duration of exposure Virulence of M. tuberculosis strain Environment of exposure Room size, air circulation
![Page 36: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/36.jpg)
CoughNot a cough
![Page 37: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/37.jpg)
Fennelly 2015
![Page 38: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/38.jpg)
Administrative Reduce risk of exposure
Environmental Prevent spread and reduce concentration of
droplet nuclei Personal Respiratory Protection Further reduce risk of exposure in special areas
and circumstances
Slide courtesy Dr. E. Jane Carter
![Page 39: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/39.jpg)
Less Transmission More Transmission
![Page 40: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/40.jpg)
Less Transmission More Transmission
![Page 41: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/41.jpg)
Less Transmission More Transmission
SAMJ, S. Afr. med. j. vol.102 n.8 Cape Town Aug. 2012
![Page 42: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/42.jpg)
The best way to stop transmission is to: Provide effective treatment to infectious persons as soon
as possible▪ Decreases bacterial burden▪ Decreases symptoms▪ 2 weeks of effective therapy decreases contagion dramatically
Isolate infectious persons while contagious ▪ Smear negative samples implies minimal contagion and allows for
discontinuance of isolation▪ Zero transmission occurs once the index patient is culture negative
Slide courtesy Dr. E. Jane Carter
![Page 43: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/43.jpg)
![Page 44: Christopher Vinnard, MD, MPH, MSCE Clinical Assistant](https://reader035.vdocument.in/reader035/viewer/2022080210/62e7a443e5dfb65f030b3026/html5/thumbnails/44.jpg)